Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE...
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of...
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.19 | -4.51306413302 | 4.21 | 4.45 | 3.99 | 1705 | 4.18731144 | CS |
| 4 | -1.08 | -21.1764705882 | 5.1 | 5.2 | 3.78 | 2662 | 4.23298807 | CS |
| 12 | -1.58 | -28.2142857143 | 5.6 | 5.85 | 3.78 | 1732 | 4.66187347 | CS |
| 26 | -4.38 | -52.1428571429 | 8.4 | 9 | 3.78 | 1793 | 5.06320632 | CS |
| 52 | -4.38 | -52.1428571429 | 8.4 | 9 | 3.78 | 1793 | 5.06320632 | CS |
| 156 | -4.38 | -52.1428571429 | 8.4 | 9 | 3.78 | 1793 | 5.06320632 | CS |
| 260 | -4.38 | -52.1428571429 | 8.4 | 9 | 3.78 | 1793 | 5.06320632 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
